VBI Vaccines Inc (NASDAQ:VBIV) Expected to Post Quarterly Sales of $970,000.00
Equities research analysts predict that VBI Vaccines Inc (NASDAQ:VBIV) will announce sales of $970,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for VBI Vaccines’ earnings, with estimates ranging from $940,000.00 to $1.00 million. VBI Vaccines reported sales of $2.68 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 63.8%. The company is scheduled to report its next earnings report on Monday, February 24th.
According to Zacks, analysts expect that VBI Vaccines will report full-year sales of $2.60 million for the current fiscal year, with estimates ranging from $2.59 million to $2.60 million. For the next financial year, analysts expect that the company will post sales of $16.78 million, with estimates ranging from $5.25 million to $28.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.90 million. VBI Vaccines had a negative net margin of 1,458.97% and a negative return on equity of 70.54%.
Several hedge funds have recently bought and sold shares of the stock. Wedbush Securities Inc. purchased a new position in shares of VBI Vaccines in the fourth quarter valued at $28,000. Squarepoint Ops LLC purchased a new position in shares of VBI Vaccines in the third quarter valued at $214,000. Sabby Management LLC purchased a new position in shares of VBI Vaccines in the third quarter valued at $413,000. Virtu Financial LLC purchased a new position in shares of VBI Vaccines in the third quarter valued at $122,000. Finally, State Street Corp grew its holdings in shares of VBI Vaccines by 4.3% in the third quarter. State Street Corp now owns 1,495,738 shares of the biopharmaceutical company’s stock valued at $705,000 after purchasing an additional 61,829 shares in the last quarter. 41.06% of the stock is owned by hedge funds and other institutional investors.
Shares of VBI Vaccines stock traded down $0.15 on Tuesday, hitting $1.63. 6,619,796 shares of the company traded hands, compared to its average volume of 7,811,935. The company has a current ratio of 1.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01. VBI Vaccines has a 52 week low of $0.47 and a 52 week high of $2.20. The business has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $0.79.
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Featured Story: Profit Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.